Xing Dorothy, Wirsing von König Carl Heinz, Newland Penny, Riffelmann Marion, Meade Bruce D, Corbel Michael, Gaines-Das Rose
National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, United Kingdom.
Clin Vaccine Immunol. 2009 Mar;16(3):303-11. doi: 10.1128/CVI.00372-08. Epub 2008 Dec 24.
Enzyme-linked immunosorbent assay (ELISA) has been widely used to evaluate antibody responses to pertussis vaccination and infection. A common reference serum is essential for the standardization of these assays. However, no internationally recognized reference serum is available. At the request of the Expert Committee on Biological Standardization (ECBS) of the World Health Organization (WHO), a set of four candidate international standards has been prepared. These candidate materials have been assessed for suitability and compared to the widely used U.S. reference pertussis antiserum (human) lot 3, lot 4, and lot 5 by 22 laboratories from 15 countries in an international collaborative study. Laboratories measured immunoglobulin G (IgG) and IgA antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (Fim2&3) using their established immunoassays. The results of this study showed each of the four candidates to be suitable as an international standard. With the agreement of the participants, a recommendation has been made to the ECBS that the candidate material coded 06/140 be established as the First International Standard for pertussis antiserum (human), with the following assigned international units (IU): IgG anti-PT, 335 IU/ampoule; IgA anti-PT, 65 IU/ampoule; IgG anti-FHA, 130 IU/ampoule; IgA anti-FHA, 65 IU/ampoule; IgG anti-PRN, 65 IU/ampoule; and IgA anti-PRN, 42 IU/ampoule. No formal units have been proposed for anti-Fim2&3 because most assays used a mixture of fimbrial antigens. In addition, the candidate material coded 06/142 has been proposed as a WHO working preparation for characterization of assay systems.
酶联免疫吸附测定(ELISA)已被广泛用于评估百日咳疫苗接种和感染后的抗体反应。一种通用的参考血清对于这些检测的标准化至关重要。然而,目前尚无国际认可的参考血清。应世界卫生组织(WHO)生物标准化专家委员会(ECBS)的要求,已制备了一套四种候选国际标准品。在一项国际合作研究中,来自15个国家的22个实验室对这些候选材料的适用性进行了评估,并与广泛使用的美国参考百日咳抗血清(人)批次3、批次4和批次5进行了比较。各实验室使用其既定的免疫测定方法检测了针对百日咳毒素(PT)、丝状血凝素(FHA)、百日咳黏附素(PRN)和菌毛(Fim2&3)的免疫球蛋白G(IgG)和IgA抗体。这项研究的结果表明,这四种候选品中的每一种都适合作为国际标准品。经参与者同意,已向ECBS建议将编码为06/140的候选材料确立为百日咳抗血清(人)的第一国际标准品,并给出以下指定国际单位(IU):IgG抗PT,335 IU/安瓿;IgA抗PT,65 IU/安瓿;IgG抗FHA,130 IU/安瓿;IgA抗FHA,65 IU/安瓿;IgG抗PRN,65 IU/安瓿;以及IgA抗PRN,42 IU/安瓿。对于抗Fim2&3尚未提出正式单位,因为大多数检测使用的是菌毛抗原混合物。此外,已提议将编码为06/142的候选材料作为WHO用于检测系统特性鉴定的工作制剂。